Drug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to become ...

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Endpoints News.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist

European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy · Storyflo